The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
High‐Dose, Short‐Course Levofloxacin for Community‐Acquired Pneumonia: A New Treatment Paradigm
Abstract
Levofloxacin demonstrates concentration-dependent bactericidal activity most closely related to the pharmacodynamic parameters of the ratio of area under the concentration-time curve (AUC) to minimum inhibitory concentration (MIC) and the ratio of peak plasma concentration (C(max)) to MIC. Increasing the dose of levofloxacin to 750 mg exploits these parameters by increasing peak drug concentrations, allowing for a shorter course of treatment without diminishing therapeutic benefit. This was demonstrated in a multicenter, randomized, double-blind investigation that compared levofloxacin dosages of 750 mg per day for 5 days with 500 mg per day for 10 days for the treatment of mild to severe community-acquired pneumonia (CAP). In the clinically evaluable population, the clinical success rates were 92.4% (183 of 198 persons) for the 750-mg group and 91.1% (175 of 192 persons) for the 500-mg group (95% confidence interval, -7.0 to 4.4). Microbiologic eradication rates were 93.2% and 92.4% in the 750-mg and 500-mg groups, respectively. These data demonstrate that 750 mg of levofloxacin per day for 5 days is at least as effective as 500 mg per day for 10 days for treatment of mild-to-severe CAP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Prediction Rule to Identify Low-Risk Patients with Community-Acquired Pneumonia
Fine, M. J., Auble, T. E., Yealy, D. M., Hanusa, B. H., Weissfeld, L. A., Singer, D. E., Coley, C. M., Marrie, T. J., & Kapoor, W. N. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701233360402 · Cited by 4,582
Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults
Bartlett, J. G., Dowell, S. F., Mandell, L. A., File, T. M., Musher, D. M., & Fine, M. J. (2000) · Clinical Infectious Diseases · doi:10.1086/313954 · Cited by 2,286
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101
Bartlett, J. G., & Mundy, L. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332408 · Cited by 982
Marston, B. J. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440360129015 · Cited by 909
Pharmacodynamics of Levofloxacin: A New Paradigm for Early Clinical Trials
Preston, S. L. (1998) · JAMA · doi:10.1001/jama.279.2.125 · Cited by 589
Doern, G. V., Brueggemann, A., Holley, H. P., & Rauch, A. M. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.5.1208 · Cited by 482
Blaser, J., Stone, B. B., Groner, M. C., & Zinner, S. H. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.7.1054 · Cited by 481
Drusano, G. L., Johnson, D. E., Rosen, M., & Standiford, H. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.483 · Cited by 426
Arancibia, F., Bauer, T. T., Ewig, S., Mensa, J., Gonzalez, J., Niederman, M. S., & Torres, A. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.16.1849 · Cited by 401
Cited by
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
“every 12 h, or levofloxacin, 750 mg every 24 h, assuming preserved renal function) should provide the highest probability of a favorable microbiologic and clinical response [127, 143, 144].”
BackgroundMandell, L. A., Wunderink, R. G., Anzueto, A., Bartlett, J. G., Campbell, G. D., Dean, N. C., Dowell, S. F., File, T. M., Musher, D. M., Niederman, M. S., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/511159 · Cited by 6,202
Self-citationMetlay, J. P., Waterer, G. W., Long, A. C., Anzueto, A., Brozek, J., Crothers, K., Cooley, L. A., Dean, N. C., Fine, M. J., Flanders, S. A., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201908-1581st · Cited by 3,657
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002255 · Cited by 3,652
Dellit, T. H., Owens, R. C., McGowan, J. E., Gerding, D. N., Weinstein, R. A., Burke, J. P., Huskins, W. C., Paterson, D. L., Fishman, N. O., Carpenter, C. F., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/510393 · Cited by 3,362
The Epidemiology, Pathogenesis and Treatment of Pseudomonas aeruginosa Infections
Driscoll, J. A., Brody, S. L., & Kollef, M. H. (2007) · Drugs · doi:10.2165/00003495-200767030-00003 · Cited by 884
Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia: A Randomized Trial
Christ-Crain, M., Stolz, D., Bingisser, R., Müller, C., Miedinger, D., Huber, P. R., Zimmerli, W., Harbarth, S., Tamm, M., & Müller, B. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200512-1922oc · Cited by 884
General Principles of Antimicrobial Therapy
Leekha, S., Terrell, C. L., & Edson, R. S. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0639 · Cited by 878
Combating Antimicrobial Resistance: Policy Recommendations to Save Lives
Infectious Diseases Society of America (IDSA) (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir153 · Cited by 733
Moussaoui, R. E., de Borgie, C. A. J. M., van den Broek, P., Hustinx, W. N., Bresser, P., van den Berk, G. E. L., Poley, J.-W., van den Berg, B., Krouwels, F. H., Bonten, M. J. M., et al. (2006) · BMJ · doi:10.1136/bmj.332.7554.1355 · Cited by 339
Community-acquired Pneumonia and Hospital-acquired Pneumonia
Lanks, C. W., Musani, A. I., & Hsia, D. W. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.12.008 · Cited by 297
The new antibiotic mantra-“shorter is better”.
Spellberg, B. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.3646 · Cited by 291
Uranga, A., España, P. P., Bilbao, A., Quintana, J. M., Arriaga, I., Intxausti, M., Lobo, J. L., Tomás, L., Camino, J., Nuñez, J., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.3633 · Cited by 290
Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis
Havey, T. C., Fowler, R. A., & Daneman, N. (2011) · Critical Care · doi:10.1186/cc10545 · Cited by 187
Short- versus Long-Course Antibacterial Therapy for Community-Acquired Pneumonia: A Meta-Analysis
Dimopoulos, G., Matthaiou, D. K., Karageorgopoulos, D. E., Grammatikos, A. P., Athanassa, Z., & Falagas, M. E. (2008) · Drugs · doi:10.2165/00003495-200868130-00004 · Cited by 160
Hanretty, A. M., & Gallagher, J. C. (2018) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2118 · Cited by 123
Royer, S., DeMerle, K. M., Dickson, R. P., & Prescott, H. C. (2018) · Journal of Hospital Medicine · doi:10.12788/jhm.2905 · Cited by 94
Furlan, L., Erba, L., Trombetta, L., Sacco, R., Colombo, G., Casazza, G., Solbiati, M., Montano, N., Marta, C., Sbrojavacca, R., et al. (2019) · Internal and Emergency Medicine · doi:10.1007/s11739-018-1955-2 · Cited by 9
Metadata
- Authors
- Dunbar, L. M., Wunderink, R. G., Habib, M. P., Smith, L. G., Tennenberg, A. M., Khashab, M. M., Wiesinger, B. A., Xiang, J. X., Zadeikis, N., & Kahn, J. B.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-09-15
- Volume
- 37
- Issue
- 6
- Pages
- 752-760
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2158956796
- Cited by
- 335
- References
- 17
- FWCI
- 20.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.